(Reuters) – Bristol Myers Squibb said on Wednesday the U.S. Food and Drug Administration approved the drugmaker’s combination of Opdivo and Yervoy to treat a common type of liver cancer.
The agency granted accelerated approval for the drug and further clinical trials may be required for final approval of the therapy. (https://reut.rs/2xoHuvv)
The FDA’s accelerated approval program allows a speedier market entry to medicines that fill an unmet medical need for a serious condition.
(Reporting by Trisha Roy in Bengaluru; Editing by Shailesh Kuber)
